A AND G PHARMACEUTICAL, INC.

Company Information

Company Name
A AND G PHARMACEUTICAL, INC.
Address
A AND G PHARMACEUTICAL, INC.
9130 RED BRANCH RD, STE U
COLUMBIA, MD, 21045-
Phone
n/a
URL
n/a
DUNS
963442723
Number of Employees
n/a
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,110,996.00
7
SBIR Phase II
$1,153,871.00
1
Chart code to be here

Award List

  1. Novel Targeted Therapy for Breast Cancer

    Amount: $1,153,871.00

    DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side eff ...

    SBIR Phase II 2010 Department of Health and Human Services
  2. Development of a novel serum diagnosis for breast cancer

    Amount: $99,960.00

    DESCRIPTION (provided by applicant): Each year 200,000 women in the US are diagnosed with breast cancer, and 40,000 women will die of the disease. Serum diagnosis for screening breast cancer patients ...

    SBIR Phase I 2004 Department of Health and Human Services
  3. Novel Targeted Therapy for Breast Cancer

    Amount: $120,600.00

    DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side eff ...

    SBIR Phase I 2007 Department of Health and Human Services
  4. Novel Small Molecule Inhibitor of Rheumatoid Arthritis

    Amount: $184,029.00

    DESCRIPTION (provided by applicant): Lck is a Src family non-receptor tyrosine kinase expressed by T lineage lymphocytes. In T cells, Lck plays an essential role in the generation of antigen-mediated ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Serum GP88 biomarker as a surrogate marker for disease progression in breast canc

    Amount: $113,320.00

    DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies

    Amount: $193,879.00

    DESCRIPTION (provided by applicant): Lung Cancer remains the leading cause of cancer and mortality for men and women worldwide. In 2010, there were 222,520 new cases of lung cancer diagnosed in t ...

    SBIR Phase I 2012 Department of Health and Human Services
  7. NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY

    Amount: $199,380.00

    Aromatase Inhibitors (AI) are the preferred hormonal treatment for estrogen receptor positive Breast Cancer (BC) in postmenopausal women and are used to treat approximately 140,000 patients annually i ...

    SBIR Phase I 2012 Department of Health and Human Services
  8. IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0

    Amount: $199,828.00

    The purpose of this application is to develop realiable, renewable, cost effective, specific, high affinity antipeptide affitnity reagent to be successfully used in mass spec based cancer biomarker de ...

    SBIR Phase I 2013 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government